Vaccine and adjuvant design for emerging viruses mutations, deletions, segments and signaling

Gavin C. Bowick, Alexander J. Mcauley

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Vaccination is currently the mosteffective strategy to medically controlviral diseases. However, developingvaccines is a long and expensive processand traditional methods, such as attenuatingwild-type viruses by serial passage,may not be suitable for all virusesand may lead to vaccine safety considerations,particularly in the case of thevaccination of particular patient groups,such as the immunocompromised andthe elderly. In particular, developing vaccinesagainst emerging viral pathogensadds a further level of complexity, asthey may only be administered to smallgroups of people or only in response toa specific event or threat, limiting ourability to study and evaluate responses.In this commentary, we discuss hownovel techniques may be used to engineera new generation of vaccine candidatesas we move toward a more targetedvaccine design strategy, driven by ourunderstanding of the mechanisms ofviral pathogenesis, attenuation and thesignaling events which are required todevelop a lasting, protective immunity.We will also briefly discuss the potentialfuture role of vaccine adjuvants, whichcould be used to bridge the gap betweenvaccine safety and lasting immunityfrom a single vaccination.

Original languageEnglish (US)
Pages (from-to)129-135
Number of pages7
JournalBioengineered Bugs
Volume2
Issue number3
DOIs
StatePublished - 2011

Fingerprint

Vaccines
Sequence Deletion
Viruses
Vaccination
Serial Passage
Safety
Immunity

Keywords

  • Adjuvants
  • Arenaviruses
  • Biodefense
  • Bunyaviruses
  • Emerging viruses
  • Filoviruses
  • Flaviviruses
  • Viral vaccines

ASJC Scopus subject areas

  • Bioengineering
  • Biotechnology
  • Applied Microbiology and Biotechnology

Cite this

Vaccine and adjuvant design for emerging viruses mutations, deletions, segments and signaling. / Bowick, Gavin C.; Mcauley, Alexander J.

In: Bioengineered Bugs, Vol. 2, No. 3, 2011, p. 129-135.

Research output: Contribution to journalArticle

Bowick, Gavin C. ; Mcauley, Alexander J. / Vaccine and adjuvant design for emerging viruses mutations, deletions, segments and signaling. In: Bioengineered Bugs. 2011 ; Vol. 2, No. 3. pp. 129-135.
@article{d36455ee56704448a123263602b2e2fd,
title = "Vaccine and adjuvant design for emerging viruses mutations, deletions, segments and signaling",
abstract = "Vaccination is currently the mosteffective strategy to medically controlviral diseases. However, developingvaccines is a long and expensive processand traditional methods, such as attenuatingwild-type viruses by serial passage,may not be suitable for all virusesand may lead to vaccine safety considerations,particularly in the case of thevaccination of particular patient groups,such as the immunocompromised andthe elderly. In particular, developing vaccinesagainst emerging viral pathogensadds a further level of complexity, asthey may only be administered to smallgroups of people or only in response toa specific event or threat, limiting ourability to study and evaluate responses.In this commentary, we discuss hownovel techniques may be used to engineera new generation of vaccine candidatesas we move toward a more targetedvaccine design strategy, driven by ourunderstanding of the mechanisms ofviral pathogenesis, attenuation and thesignaling events which are required todevelop a lasting, protective immunity.We will also briefly discuss the potentialfuture role of vaccine adjuvants, whichcould be used to bridge the gap betweenvaccine safety and lasting immunityfrom a single vaccination.",
keywords = "Adjuvants, Arenaviruses, Biodefense, Bunyaviruses, Emerging viruses, Filoviruses, Flaviviruses, Viral vaccines",
author = "Bowick, {Gavin C.} and Mcauley, {Alexander J.}",
year = "2011",
doi = "10.4161/bbug.2.3.15367",
language = "English (US)",
volume = "2",
pages = "129--135",
journal = "Bioengineered",
issn = "2165-5979",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - Vaccine and adjuvant design for emerging viruses mutations, deletions, segments and signaling

AU - Bowick, Gavin C.

AU - Mcauley, Alexander J.

PY - 2011

Y1 - 2011

N2 - Vaccination is currently the mosteffective strategy to medically controlviral diseases. However, developingvaccines is a long and expensive processand traditional methods, such as attenuatingwild-type viruses by serial passage,may not be suitable for all virusesand may lead to vaccine safety considerations,particularly in the case of thevaccination of particular patient groups,such as the immunocompromised andthe elderly. In particular, developing vaccinesagainst emerging viral pathogensadds a further level of complexity, asthey may only be administered to smallgroups of people or only in response toa specific event or threat, limiting ourability to study and evaluate responses.In this commentary, we discuss hownovel techniques may be used to engineera new generation of vaccine candidatesas we move toward a more targetedvaccine design strategy, driven by ourunderstanding of the mechanisms ofviral pathogenesis, attenuation and thesignaling events which are required todevelop a lasting, protective immunity.We will also briefly discuss the potentialfuture role of vaccine adjuvants, whichcould be used to bridge the gap betweenvaccine safety and lasting immunityfrom a single vaccination.

AB - Vaccination is currently the mosteffective strategy to medically controlviral diseases. However, developingvaccines is a long and expensive processand traditional methods, such as attenuatingwild-type viruses by serial passage,may not be suitable for all virusesand may lead to vaccine safety considerations,particularly in the case of thevaccination of particular patient groups,such as the immunocompromised andthe elderly. In particular, developing vaccinesagainst emerging viral pathogensadds a further level of complexity, asthey may only be administered to smallgroups of people or only in response toa specific event or threat, limiting ourability to study and evaluate responses.In this commentary, we discuss hownovel techniques may be used to engineera new generation of vaccine candidatesas we move toward a more targetedvaccine design strategy, driven by ourunderstanding of the mechanisms ofviral pathogenesis, attenuation and thesignaling events which are required todevelop a lasting, protective immunity.We will also briefly discuss the potentialfuture role of vaccine adjuvants, whichcould be used to bridge the gap betweenvaccine safety and lasting immunityfrom a single vaccination.

KW - Adjuvants

KW - Arenaviruses

KW - Biodefense

KW - Bunyaviruses

KW - Emerging viruses

KW - Filoviruses

KW - Flaviviruses

KW - Viral vaccines

UR - http://www.scopus.com/inward/record.url?scp=79960268756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960268756&partnerID=8YFLogxK

U2 - 10.4161/bbug.2.3.15367

DO - 10.4161/bbug.2.3.15367

M3 - Article

C2 - 21637006

AN - SCOPUS:79960268756

VL - 2

SP - 129

EP - 135

JO - Bioengineered

JF - Bioengineered

SN - 2165-5979

IS - 3

ER -